Gary Pisano
Director/Board Member at Generate Biomedicines, Inc.
Net worth: 1 472 $ as of 2023-12-30
Profile
Gary P.
Pisano is the founder of XiMo AG.
He currently holds the position of Director at Celixir Plc and Generate Biomedicines, Inc. He is also an Academic Partner at Flagship Pioneering.
In addition, he has been a Professor at Harvard Business School since 1988.
Previously, he served as an Independent Director at Axcella Health, Inc. from 2011 to 2023.
He was also a Non-Executive Director at Cell Therapy Ltd.
Furthermore, he held the position of Director at Sio Gene Therapies, Inc. from 2016 to 2017 and served as an Independent Non-Executive Director at Patheon NV during the same period.
Dr. Pisano completed his undergraduate degree at Yale University and obtained a doctorate from the University of California, Berkeley.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
AXCELLA HEALTH, INC.
0.12% | 2023-10-30 | 3,671 ( 0.12% ) | 1 472 $ | 2023-12-30 |
Gary Pisano active positions
Companies | Position | Start |
---|---|---|
Harvard Business School | Corporate Officer/Principal | 1987-12-31 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Director/Board Member | - |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Director/Board Member | - |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2021-12-31 |
Former positions of Gary Pisano
Companies | Position | End |
---|---|---|
AXCA HEALPAR | Director/Board Member | 2023-10-31 |
PATHEON N.V. | Director/Board Member | 2017-08-28 |
SIO GENE THERAPIES INC. | Director/Board Member | 2017-06-05 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Director/Board Member | - |
XiMo AG
XiMo AG Chemicals: SpecialtyProcess Industries XiMo AG develops catalysts for the metathesis of organic compounds. The firm catalyst development, process development and reactor design. The firm serves in the area of agrochemicals, flavors and fragrances, pharmaceuticals, polymers, oils and waxes and surface treatments sectors. The company was founded by Richard Schrock and Amir Hoveyda in 2010 and is headquartered in Lucerne, Switzerland. | Founder | - |
Training of Gary Pisano
Yale University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AXCA HEALPAR | Health Technology |
Private companies | 7 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
XiMo AG
XiMo AG Chemicals: SpecialtyProcess Industries XiMo AG develops catalysts for the metathesis of organic compounds. The firm catalyst development, process development and reactor design. The firm serves in the area of agrochemicals, flavors and fragrances, pharmaceuticals, polymers, oils and waxes and surface treatments sectors. The company was founded by Richard Schrock and Amir Hoveyda in 2010 and is headquartered in Lucerne, Switzerland. | Process Industries |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Patheon NV
Patheon NV Pharmaceuticals: MajorHealth Technology Patheon NV engages in the provision of pharmaceutical development and manufacturing services. It focuses on drug development, clinical trial logistics, and commercial manufacturing. The company was founded on December 24, 2013 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Sio Gene Therapies, Inc.
Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Health Technology |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Health Technology |
- Stock Market
- Insiders
- Gary Pisano